Abstract
Tumor necrosis factor inhibitors (TNFI) are novel therapies used to treat ankylosing spondylitis (AS). Demyelinating disease is a rare but serious complication of TNFI. We report a patient with a case of AS who developed demyelinating disease secondary to TNFI and was treated successfully with rituximab.
MeSH terms
-
Adalimumab
-
Adult
-
Anti-Inflammatory Agents / administration & dosage
-
Anti-Inflammatory Agents / adverse effects*
-
Antibodies, Monoclonal / administration & dosage
-
Antibodies, Monoclonal / adverse effects
-
Antibodies, Monoclonal, Humanized / administration & dosage
-
Antibodies, Monoclonal, Humanized / adverse effects*
-
Antibodies, Monoclonal, Murine-Derived / administration & dosage*
-
Antirheumatic Agents / administration & dosage*
-
Demyelinating Diseases / chemically induced*
-
Demyelinating Diseases / drug therapy
-
Etanercept
-
Female
-
Humans
-
Immunoglobulin G / administration & dosage
-
Infliximab
-
Magnetic Resonance Imaging
-
Receptors, Tumor Necrosis Factor / administration & dosage
-
Rituximab
-
Severity of Illness Index
-
Spondylitis, Ankylosing / drug therapy*
-
Spondylitis, Ankylosing / physiopathology
-
Treatment Outcome
-
Tumor Necrosis Factor-alpha / antagonists & inhibitors*
Substances
-
Anti-Inflammatory Agents
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Humanized
-
Antibodies, Monoclonal, Murine-Derived
-
Antirheumatic Agents
-
Immunoglobulin G
-
Receptors, Tumor Necrosis Factor
-
Tumor Necrosis Factor-alpha
-
Rituximab
-
Infliximab
-
Adalimumab
-
Etanercept